P01 Administrative Core

P01 行政核心

• 批准号: 10024957
• 负责人: Cesar Augusto Arias
• 金额: $ 16.95万
• 依托单位: UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10024957
• 关键词: Accountability; Address; Advisory Committees; Agriculture; Antibiotic Resistance; Antibiotics; Antimicrobial Resistance; Benchmarking; Budgets; Clinical; Clinical Data; Clostridium difficile; Collaborations; Combating Antibiotic Resistant Bacteria; Communication; Critical Illness; Data; Decision Making; Development; Diagnostic; Disease Progression; Disputes; Effectiveness; Ensure; Enterobacteriaceae; Extended-spectrum β-lactamase; Genomics; Goals; Government; Home environment; Human Resources; Immunocompromised Host; Industrialization; Infection; Intensive Care Units; Leadership; Life; Liquid substance; Logistics; Mediating; Medical; Medical center; Minor; Modern Medicine; Monitor; Online Systems; Operations Research; Organism; Pathogenicity; Patients; Persons; Phenotype; Positioning Attribute; Process; Productivity; Program Reviews; Progress Reports; Proteomics; Public Health; Quality Control; Regimen; Research; Research Activity; Research Personnel; Research Project Grants; Resolution; Sampling; System; Techniques; Texas; Therapeutic; Translating; United Nations; United States National Institutes of Health; Vancomycin resistant enterococcus; Work; carbapenemase; clinical practice; commensal microbes; conflict resolution; data management; data sharing; functional genomics; gastrointestinal; gut colonization; gut microbiota; high risk; improved outcome; insight; meetings; metabolomics; microbiota; microorganism; mortality; multi-drug resistant pathogen; novel; outcome prediction; pathogen; programs; sample collection; success; synergism; treatment strategy

ABSTRACT (Administrative Core) The clinical introduction of antibiotics in 1930s-40s represented a major medical breakthrough enabling many advances in modern medicine, agriculture and industrial practice. Unfortunately, the rise of antibiotic-resistant microorganisms globally is now considered one of the most challenging public health threats of the 21st century. The call for action against the threat of antibiotic resistance has now reached the highest level of government including the Office of the US President (with the creation of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria) and the initiative for global action by the United Nations, among others. Vancomycin-resistant enterococci (VRE), Enterobacteriaceae carrying extended spectrum β-lactamases and carbapenemases (ESBL-E/CRE), and Clostridiodes difficile are particularly concerning for high-risk patients who are immunocompromised and/or admitted to intensive care units (ICUs). Having the potential to cause life- threatening infections, particularly in those patients who have already been subjected to multiple antibiotic regimens, each of these organisms colonize the intestines, and their presence impacts subsequent colonization by other pathogens further contributing to serious disease progression and even mortality in these high-risk patients. Although these pathogens have been studied in isolation, elucidation of the dynamic interactions between pathogens and commensal gut microbiota and their implication for predicting outcomes and, thus, treatment strategies is more urgent than ever and requires a strategic, coordinated effort. The Texas Medical Center in Houston, Texas is home to several world leaders in antimicrobial resistance research and clinical practice with patient access and tremendous expertise in the cutting-edge genomic and phenotypic techniques who are uniquely positioned to perform concerted and synergistic systems-level studies of the multiple players that must be understood to address this challenge. These experts have recognized this exceptional opportunity and the strength of addressing the critical and unmet challenge through the formation of a multi-institutional collaborative research program Dynamics of Colonization and Infection by Multidrug- Resistant Pathogens in Immunocompromised and Critically Ill Patients (DYNAMITE). Crucial for the effectiveness of this multi-institutional research effort, is dedicated centralized administrative oversight and support. The Administrative Core will serve as the central “hub” for program oversight, accountability, communication, and project/process coordination for the three Projects and the Functional Genomics Core. To achieve these goals, the Administrative Core will provide integrative accountability and oversight through the Executive Leadership Team and the Internal and External Advisory Committees, and administrative support for all project leaders, research personnel, key collaborators and advisors, and institutional administrative liaisons.

摘要（行政核心） 1930年代至40年代抗生素的临床介绍代表了一个重大的医学突破，使许多人能够 现代医学，农业和工业实践的进步。不幸的是，抗生素的兴起 现在，全球微生物被认为是21世纪最具挑战性的公共卫生威胁之一。 呼吁针对抗生素抗性威胁的采取行动已达到最高水平的政府 包括美国总统办公室（由总统咨询委员会成立 抗生素耐药细菌）和联合国全球行动的倡议等。 万古霉素耐药肠球菌（VRE），肠杆菌科携带扩展光谱β-内酰胺酶和 碳青霉酶（ESBL-E/CRE）和梭状芽胞杆菌艰难梭菌特别关注高危患者 被免疫功能低下和/或被接受重症监护病房（ICU）的人。有可能导致生命的潜力 - 威胁感染，特别是在已经受到多种抗生素的患者中 方案，这些生物中的每一个都在肠道上定居，它们的存在会影响随后的殖民化 其他病原体进一步促进了这些高风险的严重疾病进展甚至死亡率 尽管这些病原体已经孤立地研究了这些病原体，但阐明了动态相互作用 在病原体和共生肠道微生物群之间以及它们对预测结果的影响和， 因此，治疗策略比以往任何时候都更加紧迫，需要一项战略性，协调的努力。德克萨斯州 德克萨斯州休斯敦的医疗中心是抗菌抗药性研究的几位世界领导人的所在地 临床实践，具有患者的访问和尖端基因组和表型方面的巨大专业知识 具有独特定位的技术，可以对 必须理解以应对这一挑战的多个球员。这些专家已经意识到了这一点 杰出的机会以及通过形成解决关键和未得到满足挑战的力量 多机构殖民和感染的多机构合作研究计划动态 免疫功能低下和重症患者（炸药）中的抗性病原体。对 这项多机构研究工作的有效性，是专门的集中行政监督， 支持。行政核心将作为计划监督，问责制， 沟通以及三个项目和功能基因组核心的项目/过程协调。到 实现这些目标，行政核心将通过 执行领导团队以及内部和外部咨询委员会，以及对 所有项目负责人，研究人员，主要合作者和顾问以及机构行政联络人。